ROsuvastatin LOading and Clinical Outcomes Trial

Phase 3CompletedNCT01936805

Yuksek Ihtisas Hospital299 enrolled

Overview

The aim of the present study was to evaluate the effect of pre-procedural single high loading dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and composite of death or myocardial infarction from cardiovascular (CV) causes, target vessel revascularization (TVR), or stroke.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

299

Conditions

Atherosclerosis

Interventions

RosuvastatinDRUG

A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * statin-naive patients * stable ischemic heart disease * de novo lesions appropriate for PCI Exclusion Criteria: * current statin use * statin allergic patients * acute coronary syndromes * lesions not appropriate for PCI * refusal for participation * statin quitting during follow- up

Locations (1)

Yuksek Ihtisas Hospital

Ankara, Altindag, Turkey (Türkiye)

Outcomes

Primary Outcomes

all cause death and composite of death or myocardial infarction from CV causes, TVR, or stroke

Time frame: 4 year

Secondary Outcomes

all cause death

Time frame: 4 year

composite of death or myocardial infarction from CV causes, TVR, or stroke

Time frame: 4 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.